Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

Faron publishes study highlighting role of sClever-1 as immune blocker in cancer

The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells

Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion

Elpiscience and Astellas collaborate for novel bispecific macrophage engager

Elpiscience will receive up to US $37 million, including the upfront payment and license option fees

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients

The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)

Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics

Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note